These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 9741957)

  • 1. In vivo metabolism of a novel cholecystokinin B (CCK-B) antagonist in rat and dog plasma and rat faeces.
    Kajbaf M; Marchioro C; Barnaby JR; Pellegatti M
    Xenobiotica; 1998 Aug; 28(8):785-94. PubMed ID: 9741957
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolism of a novel CCK-B antagonist in rat, dog and human liver microsomes.
    Kajbaf M; Rossato P; Barnaby JR; Pellegatti M
    Xenobiotica; 1998 Feb; 28(2):167-78. PubMed ID: 9522441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro metabolism of GV150013X by using liver microsomes and liver tissue slices from different species.
    Kajbaf M; Rossato P; Ferrari L; Grossi P; Pellegatti M
    Eur J Drug Metab Pharmacokinet; 1997; 22(4):359-66. PubMed ID: 9512935
    [TBL] [Abstract][Full Text] [Related]  

  • 4. (3R)-N-(1-(tert-butylcarbonylmethyl)-2,3-dihydro-2-oxo-5-(2-pyridyl)-1H-1,4-benzodiazepin-3-yl)-N'-(3-(methylamino)phenyl)urea (YF476): a potent and orally active gastrin/CCK-B antagonist.
    Semple G; Ryder H; Rooker DP; Batt AR; Kendrick DA; Szelke M; Ohta M; Satoh M; Nishida A; Akuzawa S; Miyata K
    J Med Chem; 1997 Jan; 40(3):331-41. PubMed ID: 9022799
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantitation of a new cholecystokinin and gastrin receptor antagonist (L-365,260) in dog and rat plasma by high-performance liquid chromatography.
    Chen IW; Lin JH; Dorley J
    J Chromatogr; 1992 May; 576(2):363-7. PubMed ID: 1400726
    [TBL] [Abstract][Full Text] [Related]  

  • 6. YF476 is a new potent and selective gastrin/cholecystokinin-B receptor antagonist in vitro and in vivo.
    Takinami Y; Yuki H; Nishida A; Akuzawa S; Uchida A; Takemoto Y; Ohta M; Satoh M; Semple G; Miyata K
    Aliment Pharmacol Ther; 1997 Feb; 11(1):113-20. PubMed ID: 9042983
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HPLC-NMR with severe column overloading: fast-track metabolite identification in urine and bile samples from rat and dog treated with [14C]-ZD6126.
    Lenz EM; D'Souza RA; Jordan AC; King CD; Smith SM; Phillips PJ; McCormick AD; Roberts DW
    J Pharm Biomed Anal; 2007 Feb; 43(3):1065-77. PubMed ID: 17030109
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biological properties of the benzodiazepine amidine derivative L-740,093, a cholecystokinin-B/gastrin receptor antagonist with high affinity in vitro and high potency in vivo.
    Patel S; Smith AJ; Chapman KL; Fletcher AE; Kemp JA; Marshall GR; Hargreaves RJ; Ryecroft W; Iversen LL; Iversen SD
    Mol Pharmacol; 1994 Nov; 46(5):943-8. PubMed ID: 7969084
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological profile of (R)-1-[2,3-dihydro-1-(2'-methylphenacyl)-2-oxo- 5-phenyl-1H-1,4-benzodiazepin-3-yl]-3-(3-methylphenyl)urea (YM022), a new potent and selective gastrin/cholecystokinin-B receptor antagonist, in vitro and in vivo.
    Nishida A; Miyata K; Tsutsumi R; Yuki H; Akuzawa S; Kobayashi A; Kamato T; Ito H; Yamano M; Katuyama Y
    J Pharmacol Exp Ther; 1994 May; 269(2):725-31. PubMed ID: 7910212
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of cholecystokinin peptides and GV 150013, a selective cholecystokininB receptor antagonist, on electrically evoked endogenous GABA release from rat cortical slices.
    Ferraro L; Beani L; Trist D; Reggiani A; Bianchi C
    J Neurochem; 1999 Nov; 73(5):1973-81. PubMed ID: 10537055
    [TBL] [Abstract][Full Text] [Related]  

  • 11. YM022 [(R)-1-[2,3-dihydro-1-(2'-methylphenacyl)-2-oxo-5-phenyl-1H-1,4- benzodiazepin-3-yl]-3-(3-methylphenyl)urea]: an irreversible cholecystokinin type-B receptor antagonist.
    Dunlop J; Brammer N; Evans N; Ennis C
    Biochem Pharmacol; 1997 Jul; 54(1):81-5. PubMed ID: 9296353
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antidepressant-like effects of CCK(B) receptor antagonists: involvement of the opioid system.
    Hernando F; Fuentes JA; Fournié-Zaluski MC; Roques BP; Ruiz-Gayo M
    Eur J Pharmacol; 1996 Dec; 318(2-3):221-9. PubMed ID: 9016909
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cholecystokinin B antagonists strongly potentiate antinociception mediated by endogenous enkephalins.
    Valverde O; Maldonado R; Fournie-Zaluski MC; Roques BP
    J Pharmacol Exp Ther; 1994 Jul; 270(1):77-88. PubMed ID: 8035345
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A new potent and selective non-peptide gastrin antagonist and brain cholecystokinin receptor (CCK-B) ligand: L-365,260.
    Lotti VJ; Chang RS
    Eur J Pharmacol; 1989 Mar; 162(2):273-80. PubMed ID: 2721567
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Excretion and metabolism of recainam, a new anti-arrhythmic drug, in laboratory animals and humans.
    Scatina JA; Wells DS; Kimmel HB; Kemper CJ; Sisenwine SF
    Drug Metab Dispos; 1990; 18(5):746-52. PubMed ID: 1981731
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolite profiling and identification of triptolide in rats.
    Liu J; Li L; Zhou X; Chen X; Huang H; Zhao S; Li X; Zhong D
    J Chromatogr B Analyt Technol Biomed Life Sci; 2013 Nov; 939():51-8. PubMed ID: 24096206
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Second generation "peptoid" CCK-B receptor antagonists: identification and development of N-(adamantyloxycarbonyl)-alpha-methyl-(R)-tryptophan derivative (CI-1015) with an improved pharmacokinetic profile.
    Trivedi BK; Padia JK; Holmes A; Rose S; Wright DS; Hinton JP; Pritchard MC; Eden JM; Kneen C; Webdale L; Suman-Chauhan N; Boden P; Singh L; Field MJ; Hill D
    J Med Chem; 1998 Jan; 41(1):38-45. PubMed ID: 9438020
    [TBL] [Abstract][Full Text] [Related]  

  • 18. JNJ-26070109 [(R)4-bromo-N-[1-(2,4-difluoro-phenyl)-ethyl]-2-(quinoxaline-5-sulfonylamino)-benzamide]: a novel, potent, and selective cholecystokinin 2 receptor antagonist with good oral bioavailability.
    Morton MF; Barrett TD; Freedman J; Li L; Rizzolio MC; Prendergast CE; Wu X; Moreno V; Pyati J; Figueroa K; Cagnon L; Lagaud G; Ver Donck L; Ghoos E; Allison B; Rabinowitz MH; Shankley NP
    J Pharmacol Exp Ther; 2011 Jul; 338(1):328-36. PubMed ID: 21493750
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preferential blockade of cholecystokinin-8S-induced increases in aspartate and glutamate levels by the CCK(B) receptor antagonist, L-365,260, in rat brain.
    Ge J; Long SK; Kilpatrick IC
    Eur J Pharmacol; 1998 Mar; 345(2):163-70. PubMed ID: 9600632
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disposition and metabolism of a novel diurea inhibitor of acyl CoA: cholesterol acyltransferase (YM17E) in the rat and dog.
    Uchida T; Nakamura E; Usui T; Imasaki H; Kawakami R; Watanabe T; Higuchi S
    Xenobiotica; 1994 Dec; 24(12):1223-36. PubMed ID: 7771109
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.